PharmaEssentia announced yesterday (June 5) that its consolidated revenue for May reached NT$1.18 billion, representing a 49.15% year-over-year increase. The strong performance was primarily fueled by stable sales of its rare blood cancer therapy, Ropeginterferon alfa-2b (Ropeg or P1101), in the U.S. market.

The company noted that while exchange rate fluctuations impacted May revenue, Ropeg sales in the U.S. continued to grow when excluding currency effects. Since the beginning of the year, the number of new prescribing physicians and patients has continued to rise, reflecting the drug’s growing recognition and endorsement among both doctors and patients.

To accelerate its global expansion and sales momentum, PharmaEssentia’s U.S. subsidiary recently completed a planned restructuring and expansion of its sales team. This month, the company’s executive team traveled to the U.S. to lead a marketing training summit as part of its full-scale push for the “Global 3M” strategy, which integrates Medical, Marketing, and Market Access efforts to strengthen execution and lay the foundation for 2025 growth. The initiative is aimed at improving access for patients with myeloproliferative neoplasms (MPNs) worldwide.

In January this year, PharmaEssentia announced that the Phase III clinical trial “SURPASS ET,” evaluating Ropeg for the treatment of essential thrombocythemia (ET), met its primary endpoint with statistically significant results (p-value = 0.0001). The company confirmed that the clinical study report (CSR) has been finalized and expects to formally request a meeting with the U.S. FDA in mid-June, with plans to submit a New Drug Application for ET within the year. Additionally, the company intends to file for regulatory approval for Ropeg in ET in Japan, China, and South Korea in the third quarter of this year.

Resource: 藥華藥5月合併營收年增49% 血癌藥銷售穩定